This is a news story, published by USA Today, that relates primarily to Victoza news.
For more Victoza news, you can click here:
more Victoza newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from USA Today, you can click here:
more news from USA TodayOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
generic drug applications. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest previous medications news, diabetes patients news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
OzempicUSA Today
•
75% Informative
The new drug, sold under the name Victoza , follows the approval of the generic GLP-1 exanatide last month .
Neither drug is as effective as the brand-name weekly injections sold for diabetes and weight loss.
Having more options "could indeed impact the prescribing landscape," Dr. Fatima Cody Stanford , a weight loss specialist.
VR Score
82
Informative language
85
Neutral language
70
Article tone
semi-formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links